Home / Posts Tagged "Peter Bains"

Second quarter revenue from operations grows 4% sequentially and 2% year-on-year to Rs. 911 Cr 1st half revenue from operations up 6% Syngene International Limited today announced financial results for the second quarter and half year of FY26.   Quarterly Financial Highlights (All numbers are in Indian Rupees in Cr except margins)     Q2 FY25 Q2 FY26 YoY Change (%) Revenue from Operations 891 911 2% Reported Revenue 908 926 2% Reported EBITDA 261 215 -18% Reported EBITDA margin (%) 28.8% 23.2%   Reported PAT (before exceptional items) 106 67 -37% Reported PAT Margin (%) 11.7% 7.3%   H1 FY26 Financial Highlights (All numbers are in Indian rupees in Crores except margins)     H1 FY25 H1 FY26 YoY Change (%) Revenue from Operations 1,681 1,785 6% Reported Revenue 1,715 1,818 6% Reported EBITDA 449 439 -2% Reported EBITDA margin (%) 26.2% 24.1%   Reported PAT (before exceptional items) 161* 154 -4% Reported PAT Margin (%) 9.4% 8.5%   Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim.   Commenting on the results, Peter Bains, Managing Director and CEO, Syngene International Limited, said, “Our Q2 performance was driven by underlying revenue growth from research

READ MORE

Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced site upgrades to accelerate drug discovery and development, helping clients bring novel therapies to market faster. The investments included a dedicated, state-of-the-art

READ MORE